A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 Treatment of Recurrent Herpes Labialis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 May 2018
Price : $35 *
At a glance
- Drugs NB 001 (Primary)
- Indications Herpes labialis
- Focus Registrational; Therapeutic Use
- Sponsors BlueWillow Biologics
- 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
- 13 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Mar 2013 Planned number of patients changed from 270 to 380, as reported by ClinicalTrials.gov.